IP Library Granted Patent US 8,946,433
Granted Patent B2
US 8,946,433 · App. 13/233,227 · Granted Feb 3, 2015

Process for the preparation of sufentanil base and related compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,433
App. No.
13/233,227
Granted
Feb 3, 2015
Kind
B2
Abstract

The present disclosure generally related to an improved process for the preparation of various piperidine derivatives. More particularly, the present disclosure related to an improved process for preparing sufentanil base (1) and related compounds, which advantageously utilizes more cost effective and/or less hazardous reagents, including a dispersion comprising between about 50% and about 70% by weight (based on the total weight of the dispersion) of an alkali metal hydride, such as sodium hydride, as well as eliminates the need for expensive and/or time consuming purification techniques.

Claims (29)

1. A process for preparing a compound of Formula (3),

the process comprising:

(i) contacting a substituted 4-hydroxymethyl-4-aminopiperidine of Formula (2)

with a dispersion comprising between about 50 and about 70% by weight (based on the total weight of the dispersion) alkali metal hydride in the presence of an alcohol catalyst and an organic solvent selected from the group consisting of N, N-dimethyl tormamide (DMF), 1methyl-2-pyrrolidinone (NMP), dimethoxy ethane (glyme), diethylene glycol diethyl ether (diglyme), dimethyl sulfoxide (DMSO), and combinations thereof, to deprotonate the hydroxyl group of the substituted 4-hydroxymethyl-4-aminopiperidine; and,

(ii) reacting an alkylating agent with the deprotonated, substituted 4-hydroxymethyl-4 aminopiperidine to form the compound of Formula (3).

2. The process of claim 1 , wherein the alkylating agent is a methylating agent.

3. The process of claim 1 , wherein the alcohol catalyst is selected from the group consisting of methanol, ethanol, isopropanol, t-butanol or a combination thereof.

4. The process of claim 1 , wherein the alcohol catalyst is t-butanol, and further wherein the deprotonated, substituted 4-hydroxymethyl- 4-aminopiperidine is reacted with a methyl iodide alkylating agent.

5. The process of claim 1 , wherein the organic solvent is diglyme.

6. The process of claim 1 , wherein the dispersion comprises between about 55% and about 65% by weight alkali metal hydride.

7. The process of claim 6 , wherein the dispersion comprises about 60% by weight sodium hydride in mineral oil.

8. The process of claim 1 , further comprising:

(i) dilution of a reaction mixture containing the compound of Formula (3) with water;

(ii) isolating the compound of Formula (3) from the diluted reaction mixture;

(iii) purifying the isolated compound of Formula (3) by liquid-liquid extraction, the isolated compound of Formula (3) being contacted with a solvent system comprising an organic phase and an aqueous phase at a pH between about 4.8 and about 5.4, and then the organic phase soluble compound of Formula (3) being partitioned into the aqueous phase by adjusting the pH to between about 1.8 and about 2.9; and,

(iv) isolating the partitioned compound of Formula (3) from the aqueous phase by adjusting the pH thereto to greater than about 12 by the addition of a base thereto.

9. The process of claim 8 , wherein the pH of the solvent system is between about 5.0 and about 5.2, and further wherein the pH is adjusted to between about 2.0 and about 2.7 to partition the compound of Formula (3) into the aqueous phase; and the partitioned compound of Formula (3) is isolated by adjusting the pH of the aqueous phase by the addition of a base selected from the group consisting of ammonium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium bicarbonate, potassium carbonate, sodium bicarbonate, sodium carbonate or a mixture thereof.

10. A process for preparing an amide of Formula (C) comprising:

(i) contacting a compound of Formula (2) with a dispersion comprising between about 50% and about 70% by weight (based on the total weight of the dispersion) alkali metal hydride in the presence of an alcohol catalyst and an organic solvent to deprotonate the hydroxyl group of the compound of Formula (2);

(ii) reacting an alkylating agent with the deprotonated compound of Formula (2) to form the compound of Formula (3);

(iii) contacting the compound of Formula (3) with an alkyl acid halide in an organic solvent to form the amide of Formula (C);

(iv) removing a portion of the organic solvent from the amide of Formula (C); and,

(v) collecting the amide of Formula (C);

wherein Formula (C), Formula (2), and Formula (3) are as follows:

and wherein R 1 is 2-thiophen-2-ylethyl; R 2 is methoxymethyl; and R 3 is a C 1 -C 5 alkyl.

11. The process of claim 10 wherein about 70% to about 80% (by weight) of the organic solvent is removed from the amide of Formula (C) by distillation; and the alkyl acid halide is propionyl chloride.

12. The process of claim 11 , wherein after a portion of the organic solvent has been removed, an acid is added to the amide of Formula (C) to form an acid salt thereof.

13. The process of claim 12 wherein a base is added to the acid salt of the amide of Formula (C), to form a base of the amide of Formula (C).

14. The process of claim 13 , wherein the resulting base of the amide of Formula (C) is a sufentanil base.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2011
From: ORR, BRIAN; HAAR, JOSEPH P., JR.; KLEMM, GEORGE H.; TOMAZI, KEITH G.
To: MALLINCKRODT INC.
Reel/Frame 026910/0778 →
CHANGE OF LEGAL ENTITY Recorded Sep 15, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026911/0330 →